A
Achieve Life Sciences, Inc. (ACHV)
NCM – Real Time Price. Currency in USD
6.66
-0.11 (-1.62%)
Market open: Aug 12, 2026, 10:06 AM EDT
6.77
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:54 PM EDT
Find any stock by ticker or company name

NCM – Real Time Price. Currency in USD
6.66
-0.11 (-1.62%)
Market open: Aug 12, 2026, 10:06 AM EDT
6.77
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:54 PM EDT
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
| Name | Position |
|---|---|
| Dr. Andrew D. Goldberg M.D. | CEO, President & Director |
| Mr. Erik Atkisson | Chief Legal Officer |
| Mr. Mark K. Oki CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-06 | 8-K | achv-20260702.htm |
| 2026-06-08 | DEF 14A | achv-20260604.htm |
| 2026-06-08 | ARS | proxy_2026_ars.pdf |
| 2026-06-02 | 8-K | achv-20260529.htm |
| 2026-05-29 | PRE 14A | achv-20260529.htm |
| 2026-05-19 | CORRESP | filename1.htm |
| 2026-05-12 | S-8 | achv-20260512.htm |
| 2026-05-12 | S-3 | achv-20260512.htm |
| 2026-05-12 | 8-K | d854692d8k.htm |
| 2026-04-30 | 10-K/A | achv-20251231.htm |